[Federal Register Volume 77, Number 246 (Friday, December 21, 2012)]
[Notices]
[Pages 75670-75671]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-30780]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Registration, 
AMRI Rensselaer, Inc.

    By Notice dated July 30, 2012, and published in the Federal 
Register on August 7, 2012, 77 FR 47114, AMRI Rensselaer, Inc., 33 
Riverside Avenue, Rensselaer, New York 12144, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the following basic classes of controlled 
substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Amphetamine (1100).........................  II
Lisdexamfetamine (1205)....................  II
Methylphenidate (1724).....................  II
Pentobarbital (2270).......................  II
4-Anilino-N-phenethyl-4-piperidine (8333)..  II
Meperidine (9230)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture bulk controlled substances for use 
in product development and for distribution to its customers.
    In reference to drug code 7360 (Marihuana), the company plans to 
bulk manufacture cannabidiol as a synthetic intermediate. This 
controlled substance

[[Page 75671]]

will be further synthesized to bulk manufacture a synthetic THC (7370). 
No other activity for this drug code is authorized for this 
registration.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a), and determined that the registration 
of AMRI Rensselaer, Inc., to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated AMRI Rensselaer, Inc., to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 
1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic classes of controlled substances listed.

    Dated: December 18, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-30780 Filed 12-20-12; 8:45 am]
BILLING CODE 4410-09-P